Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.
InDex Pharmaceuticals Holding AB (publ) today announced an updated timeline for patient recruitment in the ongoing phase IIb study CONDUCT with the drug candidate cobitolimod. Top line results from the study are now expected in the first half of 2019 instead of in the fourth quarter of 2018 as previously communicated.
Spago Nanomedical AB (publ) announce today that the United States Patent and Trademark Office (USPTO) has granted the company´s patent application comprising product protection for Tumorad® in the USA.
Extension builds on collaboration established in 2014. Collaboration focuses on aging and age-related diseases, including neurodegeneration and cancer.